Retatrutide vs 5-Amino-1MQ

Retatrutide (LY3437943) and 5-Amino-1MQ both feature in metabolic research, but they operate through entirely different mechanistic layers, making them complementary tools rather than alternatives. Retatrutide is a peptide — specifically, a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly. It acts at the cell surface, engaging three distinct G-protein-coupled receptors to modulate appetite, insulin secretion, and energy expenditure through coordinated hormonal signalling. It has been studied in Phase II clinical trials as part of the current investigational metabolic research pipeline. 5-Amino-1MQ is a small molecule, not a peptide, though it is catalogued alongside peptides for its overlapping research audience and metabolic focus. It works intracellularly: as a selective inhibitor of Nicotinamide N-Methyltransferase (NNMT), it redirects nicotinamide flux from methylation toward NAD+ biosynthesis via the salvage pathway, elevating intracellular NAD+ levels and downstream sirtuin activity. Where Retatrutide targets systemic hormonal regulation from the outside in, 5-Amino-1MQ targets cellular energy metabolism from the inside out. Researchers studying multi-level metabolic biology frequently study both compounds in parallel to characterise the interaction between systemic hormonal signals and intracellular metabolic reprogramming.